Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostatic Neoplasms × capivasertib × Clear all

Phase

Phase 3 2 Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6 Triple Negative Breast Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1 Advanced Gastric Cancer 1 Advanced Breast Cancer 1 Adenocarcinoma 1

Interventions

Docetaxel 122 Prednisone 105 Abiraterone Acetate 79 Leuprolide 76 enzalutamide 74 Radiotherapy 49 Goserelin 48 bicalutamide 45 Magnetic Resonance Spectroscopy 45 Androgen Antagonists 42 apalutamide 39 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 39 Radiosurgery 30 abiraterone 29 cabazitaxel 28 Gonadotropin-Releasing Hormone 26 Specimen Handling 25 Carboplatin 25 gallium 68 PSMA-11 23 darolutamide 23 Estramustine 22 Metformin 21 luprolide acetate gel depot 20 relugolix 19 Triptorelin Pamoate 19 Radiation 18 Pluvicto 18 Brachytherapy 18 sipuleucel-T 16 prednylidene 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05593497 2025-04-16

SNARE

VA Office of Research and Development

Phase 2 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡